1. A clinician is explaining to a pharmacy student why ivacaftor is effective in patients with G551D cystic fibrosis transmembrane conductance regulator (CFTR) mutations but not in patients who carry two class I nonsense mutations. Which of the following best describes the mechanism of action of ivacaftor that explains this selective efficacy?
A) It binds to misfolded CFTR protein in the endoplasmic reticulum and stabilizes its conformation, increasing the amount of protein that traffics to the apical membrane.
B) It activates protein kinase A (PKA) to phosphorylate the regulatory domain of CFTR, initiating channel opening in cells that lack functional cAMP signaling.
C) It binds to CFTR already present at the apical cell membrane and increases the probability that the channel gate opens, enhancing chloride conductance through channels with a gating defect.
D) It suppresses nonsense-mediated mRNA decay to allow read-through of premature stop codons, producing partial-length CFTR protein in class I mutation patients.
E) It inhibits the proteasomal degradation pathway that eliminates misprocessed CFTR in the endoplasmic reticulum, increasing total cellular CFTR concentration.
ANSWER: C
Rationale:
Ivacaftor is a CFTR potentiator, meaning it binds to CFTR protein already present at the apical epithelial cell membrane and increases the open probability (Po) of the channel gate, allowing chloride to flow through channels that are structurally present at the surface but fail to open normally due to a gating defect. In G551D CFTR, the protein traffics normally to the membrane but cannot open in response to ATP binding; ivacaftor directly addresses this gating dysfunction, which is why the STRIVE trial demonstrated a mean forced expiratory volume in one second as percent predicted (FEV1% predicted) improvement of 10.6 percentage points in G551D patients. In patients with two class I nonsense mutations, no functional CFTR protein reaches the apical membrane because premature stop codons trigger nonsense-mediated mRNA decay and absent or severely truncated protein is produced; a potentiator that requires surface-expressed CFTR to act upon has nothing to bind, explaining the complete lack of efficacy in class I homozygotes.
Option A: Option A is incorrect because stabilizing misfolded CFTR in the endoplasmic reticulum and improving trafficking to the apical membrane is the mechanism of CFTR correctors such as lumacaftor and tezacaftor, not potentiators.
Option B: Option B is incorrect because ivacaftor does not activate PKA or interact with the cAMP signaling cascade; CFTR phosphorylation by PKA is a prerequisite for channel activation that operates independently of ivacaftor's gating mechanism.
Option D: Option D is incorrect because suppression of nonsense-mediated mRNA decay to allow premature stop codon read-through is an investigational strategy for class I mutations and is not the mechanism of ivacaftor.
Option E: Option E is incorrect because inhibiting proteasomal degradation of misprocessed CFTR is not ivacaftor's mechanism; reducing endoplasmic reticulum-associated degradation (ERAD) is part of the corrector mechanism of action.
2. A 19-year-old with cystic fibrosis (CF) is homozygous for the phenylalanine-508 deletion (F508del) CFTR mutation. A medical student asks why F508del patients require both a corrector and a potentiator in their treatment regimen, whereas patients with G551D gating mutations are effectively treated with ivacaftor alone. Which of the following best explains why F508del-targeted therapy requires both drug classes?
A) F508del CFTR has two independent protein-level defects: a processing defect causing misfolding and endoplasmic reticulum retention, and a gating defect in the small fraction that does reach the apical membrane, so correctors and potentiators each address a distinct defect that the other cannot remedy.
B) F508del CFTR is expressed in greater abundance than G551D CFTR, requiring a second agent to downregulate excess channel production to prevent chloride overload at the apical membrane.
C) Correctors are required to block the proteasomal degradation of ivacaftor itself, preventing the drug from being eliminated before it can bind to F508del CFTR at the membrane.
D) The F508del mutation produces a CFTR protein that lacks the regulatory R domain entirely, so potentiators restore gating while correctors regenerate the R domain through post-translational modification.
E) Correctors are added to F508del regimens solely to reduce the CYP3A4-mediated hepatic metabolism of ivacaftor, extending its plasma half-life to therapeutically effective concentrations.
ANSWER: A
Rationale:
The F508del mutation produces a CFTR protein with two distinct defects that must each be pharmacologically addressed. First, F508del CFTR misfolds in the endoplasmic reticulum (ER), where it is recognized by the quality control machinery including the Hsp70/Hsp90 chaperone complex, ubiquitinated, and targeted for proteasomal degradation through endoplasmic reticulum-associated degradation (ERAD) before reaching the apical membrane; this processing defect is addressed by CFTR correctors such as lumacaftor, tezacaftor, and elexacaftor, which stabilize the misfolded protein and allow more of it to traffic to the Golgi and then to the cell surface. Second, even the small fraction of F508del CFTR that does reach the apical membrane retains a gating defect and opens with reduced probability; this residual gating defect is addressed by ivacaftor, the potentiator component of all approved F508del-targeted regimens. G551D CFTR, by contrast, folds normally and traffics to the membrane efficiently, with its only dysfunction being the inability to open; ivacaftor alone is sufficient because the corrector problem does not exist.
Option B: Option B is incorrect because F508del CFTR is not overexpressed; the defect is underrepresentation at the apical membrane due to degradation, and there is no chloride overload concern.
Option C: Option C is incorrect because correctors act on CFTR protein, not on ivacaftor pharmacokinetics; proteasomal degradation of drugs is not the mechanism being addressed.
Option D: Option D is incorrect because F508del CFTR retains its regulatory R domain; the misfolding involves the nucleotide-binding domain-1 (NBD1) region, not deletion of the R domain.
Option E: Option E is incorrect because tezacaftor and elexacaftor do not inhibit CYP3A4 or extend ivacaftor's plasma half-life; lumacaftor, conversely, induces CYP3A4 and reduces ivacaftor concentrations.
3. The STRIVE trial (Study of VX-770 in Subjects with Cystic Fibrosis and the G551D-CFTR Mutation) established ivacaftor as the first disease-modifying therapy for cystic fibrosis (CF). Which of the following best describes the primary efficacy outcome demonstrated in the STRIVE trial and its mechanistic significance?
A) A reduction in sweat chloride concentration of approximately 10 mmol/L compared with placebo over 24 weeks, confirming partial CFTR channel opening but insufficient magnitude to produce meaningful lung function improvement.
B) Stabilization of forced expiratory volume in one second as percent predicted (FEV1% predicted) with no decline over 48 weeks in G551D patients, compared with progressive decline in the placebo group, demonstrating disease-modifying slowing of deterioration.
C) A 4.0 percentage-point improvement in FEV1% predicted compared with placebo in G551D patients, consistent with the modest gains seen with lumacaftor-ivacaftor in F508del homozygotes, confirming a class-effect ceiling for CFTR modulation.
D) A mean improvement in FEV1% predicted of 10.6 percentage points compared with placebo over 48 weeks in patients aged 12 and older with at least one G551D allele, accompanied by a reduction in sweat chloride concentration of approximately 48 mmol/L, establishing CFTR modulation as a paradigm shift in CF therapy.
E) A reduction in pulmonary exacerbation rate of approximately 55 percent compared with placebo, with no statistically significant change in FEV1% predicted, suggesting that ivacaftor's primary benefit operates through anti-inflammatory rather than channel-potentiating mechanisms.
ANSWER: D
Rationale:
The STRIVE trial enrolled 161 patients aged 12 and older with at least one G551D CFTR allele and demonstrated a mean improvement in forced expiratory volume in one second as percent predicted (FEV1% predicted) of 10.6 percentage points compared with placebo over 48 weeks, along with a reduction in sweat chloride concentration of approximately 48 mmol/L and significant improvement in the CF questionnaire-revised (CFQ-R) respiratory domain score. The magnitude of the FEV1 improvement — nearly 11 percentage points in a condition that had previously seen only symptomatic therapies — was unprecedented and validated the concept that small-molecule rescue of defective CFTR protein could produce clinically meaningful lung function gains, establishing CFTR modulation as the central paradigm of modern CF pharmacotherapy.
Option A: Option A is incorrect because the sweat chloride reduction in STRIVE was approximately 48 mmol/L, not 10 mmol/L, and the FEV1 improvement was substantial, not absent.
Option B: Option B is incorrect because the STRIVE trial demonstrated active improvement in FEV1% predicted above placebo, not merely stabilization; disease stabilization with prevention of decline is an inadequate description of the trial's primary finding.
Option C: Option C is incorrect because the 4.0 percentage-point FEV1 improvement describes the lumacaftor-ivacaftor result in F508del homozygotes from the TRAFFIC/TRANSPORT trials, not the ivacaftor G551D result; the STRIVE result was substantially larger.
Option E: Option E is incorrect because the STRIVE primary endpoint was FEV1% predicted and demonstrated a statistically significant and clinically large improvement; ivacaftor's mechanism is potentiation of the CFTR channel gate, not anti-inflammatory action.
4. A 24-year-old woman with cystic fibrosis (CF) homozygous for F508del is initiated on lumacaftor-ivacaftor (Orkambi). She also takes an oral hormonal contraceptive for menstrual management. Her CF team notes that her contraceptive may become less effective and that the overall efficacy of the lumacaftor-ivacaftor regimen is partially self-limited. Which single pharmacokinetic mechanism best explains both of these observations?
A) Ivacaftor inhibits cytochrome P450 isoform CYP3A4 (CYP3A4), reducing lumacaftor metabolism and causing lumacaftor accumulation that competitively displaces the hormonal contraceptive from plasma protein binding sites, lowering free contraceptive concentrations.
B) Lumacaftor is a strong inducer of CYP3A4, which substantially reduces plasma concentrations of ivacaftor (partially attenuating potentiator efficacy) and of co-administered CYP3A4 substrates including hormonal contraceptives, whose efficacy depends on maintaining therapeutic plasma concentrations.
C) Lumacaftor inhibits intestinal P-glycoprotein efflux transporters, reducing absorption of both ivacaftor and hormonal contraceptives from the gastrointestinal tract and producing sub-therapeutic systemic exposure to both agents.
D) Ivacaftor undergoes autoinduction of its own CYP3A4-mediated metabolism after several weeks of dosing, progressively reducing its own plasma concentrations and, through an uncharacterized mechanism, also reducing hormonal contraceptive levels.
E) Lumacaftor activates the pregnane X receptor (PXR) to upregulate uridine diphosphate-glucuronosyltransferase (UGT) enzymes, accelerating glucuronidation of ivacaftor and hormonal contraceptives without involving the CYP3A4 pathway.
ANSWER: B
Rationale:
Lumacaftor is a strong inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), the primary hepatic enzyme responsible for the metabolism of ivacaftor and of many co-administered drugs including hormonal contraceptives. When lumacaftor induces CYP3A4, it markedly increases the rate of ivacaftor metabolism, reducing ivacaftor plasma concentrations and partially counteracting the potentiation benefit — this is the counterintuitive self-attenuating interaction built into the lumacaftor-ivacaftor combination product that contributes to its more modest efficacy relative to later-generation regimens. The same CYP3A4 induction accelerates the metabolism of hormonal contraceptives (estrogen and progestin components are CYP3A4 substrates), reducing their plasma concentrations below effective levels and substantially impairing contraceptive efficacy; alternative non-hormonal contraception is required for patients on lumacaftor-ivacaftor.
Option A: Option A is incorrect because ivacaftor does not inhibit CYP3A4; lumacaftor is the CYP3A4-interacting component, and protein binding displacement is not the mechanism involved.
Option C: Option C is incorrect because the lumacaftor-ivacaftor interaction involves hepatic CYP3A4 enzyme induction, not intestinal P-glycoprotein inhibition; P-gp inhibition would increase, not decrease, drug absorption.
Option D: Option D is incorrect because autoinduction of ivacaftor's own metabolism is not the established mechanism; the CYP3A4 induction is caused by lumacaftor, not by ivacaftor itself.
Option E: Option E is incorrect because while lumacaftor may have some effects on pregnane X receptor (PXR) pathways, the clinically relevant and labeled interaction is CYP3A4 induction, not UGT-mediated glucuronidation; the option also incorrectly excludes CYP3A4.
5. A pharmacist is counseling a 16-year-old newly initiated on elexacaftor-tezacaftor-ivacaftor (ETI, marketed as Trikafta) for cystic fibrosis (CF). She asks why the regimen requires two separate dosing times per day rather than a single daily dose. Which of the following correctly describes the approved ETI dosing schedule and the rationale for its twice-daily structure?
A) Two tablets are taken in the evening containing all three components (elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg), followed by one tablet of tezacaftor 50 mg in the morning, to separate corrector and potentiator peak plasma concentrations and reduce overlapping adverse effects.
B) One tablet containing all three components is taken in the morning, and a second identical three-component tablet is taken in the evening, maintaining corrector and potentiator concentrations through a straightforward twice-daily schedule with equal doses at each administration.
C) Three tablets are taken in the morning and one tablet of elexacaftor alone is taken in the evening, with this asymmetric loading designed to front-load corrector activity during waking hours when CFTR trafficking demand is highest.
D) Two tablets are taken once daily at a fixed time (either morning or evening based on tolerability), with no additional evening dose, because the 24-hour half-lives of all three components permit once-daily administration without trough concentration drops.
E) Two tablets are taken in the morning (each containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg) and one ivacaftor 150 mg tablet is taken in the evening, a schedule designed to maintain both corrector concentrations and ivacaftor potentiator concentrations throughout the full 24-hour dosing cycle.
ANSWER: E
Rationale:
The approved elexacaftor-tezacaftor-ivacaftor (ETI) dosing schedule consists of two tablets taken in the morning, each containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg, plus one tablet of ivacaftor 150 mg taken in the evening approximately 12 hours after the morning dose. This asymmetric schedule is designed to deliver the full corrector doses (elexacaftor and tezacaftor) in the morning while providing a second ivacaftor dose in the evening to sustain ivacaftor plasma concentrations — and therefore ongoing potentiator activity — throughout the full 24-hour cycle. The evening ivacaftor dose prevents an ivacaftor trough that could reduce channel-gating activity overnight, while the corrector components have pharmacokinetic profiles that permit once-daily dosing. Adherence to the fixed schedule is important for maintaining effective modulator concentrations.
Option A: Option A is incorrect because the evening dose is ivacaftor alone, not a three-component tablet; the corrector components elexacaftor and tezacaftor are dosed only in the morning.
Option B: Option B is incorrect because the two morning tablets and the evening tablet are not identical; the morning tablets contain all three components while the evening tablet contains only ivacaftor 150 mg, not a three-component formulation.
Option C: Option C is incorrect because the evening dose is ivacaftor alone, not elexacaftor; the schedule does not separate components in the manner described, and there is no evidence that CFTR trafficking demand varies by time of day.
Option D: Option D is incorrect because ETI is dosed twice daily, not once daily; the pharmacokinetic profiles of the components — particularly ivacaftor — require an evening dose to prevent trough concentrations from dropping below therapeutic levels.
6. A medical team is comparing lumacaftor-ivacaftor with tezacaftor-ivacaftor for a 28-year-old with cystic fibrosis (CF) who is F508del homozygous and also takes tacrolimus for a prior solid organ transplant. The team is specifically concerned about drug interactions at the cytochrome P450 isoform CYP3A4 (CYP3A4) level. Which of the following represents the key pharmacokinetic difference between lumacaftor and tezacaftor most relevant to this patient's management?
A) Tezacaftor is a moderate CYP3A4 inhibitor, whereas lumacaftor has no effect on CYP3A4 activity; in a patient taking tacrolimus (a CYP3A4 substrate), tezacaftor would increase tacrolimus concentrations while lumacaftor would leave them unchanged.
B) Lumacaftor undergoes extensive renal elimination requiring dose adjustment in chronic kidney disease, whereas tezacaftor is hepatically eliminated; the patient's tacrolimus-related nephrotoxicity risk makes lumacaftor a safer corrector choice.
C) Lumacaftor is a strong inducer of CYP3A4 and substantially reduces concentrations of CYP3A4 substrates including tacrolimus and ivacaftor itself, whereas tezacaftor does not induce CYP3A4, eliminating this self-attenuating interaction and the risk of tacrolimus sub-therapeutic exposure.
D) Tezacaftor is a strong inhibitor of P-glycoprotein efflux transporters, increasing tacrolimus bioavailability to potentially toxic concentrations, whereas lumacaftor has no P-glycoprotein effect; tacrolimus monitoring is therefore more critical with tezacaftor than with lumacaftor.
E) Both lumacaftor and tezacaftor are equally potent CYP3A4 inducers, but tezacaftor has a shorter half-life that allows the induction effect to resolve more rapidly when the corrector is held, making dose adjustments of tacrolimus easier to manage in clinical practice.
ANSWER: C
Rationale:
The critical pharmacokinetic distinction between the two first- and second-generation CFTR correctors is that lumacaftor is a strong inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), whereas tezacaftor does not induce CYP3A4. This distinction has major clinical consequences. In the lumacaftor-ivacaftor combination product, lumacaftor-driven CYP3A4 induction substantially reduces ivacaftor plasma concentrations, partially counteracting potentiator efficacy — the self-attenuating interaction that contributes to the more modest FEV1 improvements with lumacaftor-ivacaftor compared with later regimens. For this patient on tacrolimus — a narrow therapeutic index CYP3A4 substrate — lumacaftor's CYP3A4 induction would reduce tacrolimus trough concentrations, risking allograft rejection; this interaction is clinically dangerous and requires close tacrolimus level monitoring and likely dose escalation. Tezacaftor-ivacaftor eliminates both problems: it does not induce CYP3A4, so ivacaftor concentrations are not attenuated and tacrolimus concentrations are not reduced.
Option A: Option A is incorrect because tezacaftor is not a CYP3A4 inhibitor; the relevant difference is lumacaftor's induction, not tezacaftor's inhibition.
Option B: Option B is incorrect because the primary difference between these correctors is CYP3A4 induction, not route of elimination; neither agent requires renal dose adjustment in standard clinical practice.
Option D: Option D is incorrect because tezacaftor is not a clinically significant P-glycoprotein inhibitor; the interaction profile described is fabricated and inverts the actual clinical concern.
Option E: Option E is incorrect because lumacaftor and tezacaftor are not equivalent CYP3A4 inducers; tezacaftor does not induce CYP3A4, and the option's premise of equivalent induction is factually wrong.
7. A 22-year-old woman with cystic fibrosis (CF) on elexacaftor-tezacaftor-ivacaftor (ETI) develops allergic bronchopulmonary aspergillosis (ABPA) requiring initiation of itraconazole, a strong cytochrome P450 isoform CYP3A4 (CYP3A4) inhibitor. Which of the following is the correct management of her ETI regimen when itraconazole is co-prescribed?
A) Reduce ETI dosing frequency to every other day for the duration of itraconazole therapy per prescribing labeling, because itraconazole-driven CYP3A4 inhibition substantially increases ivacaftor plasma concentrations to potentially adverse levels at the standard daily dose.
B) Discontinue ETI entirely while itraconazole is in use and restart ETI at the standard dose 2 weeks after itraconazole completion, because no dose adjustment protocol exists for concurrent strong CYP3A4 inhibitor use with ETI.
C) Continue ETI at the standard daily dose without adjustment but add weekly liver function tests (LFTs) to monitor for combined hepatotoxicity, as the itraconazole-ETI interaction is primarily hepatic rather than pharmacokinetic.
D) Increase the ETI morning dose by one additional tablet to compensate for the expected reduction in ETI bioavailability caused by itraconazole's competitive inhibition of intestinal efflux transporters that ordinarily assist ETI absorption.
E) Switch from itraconazole to voriconazole, which is a moderate rather than strong CYP3A4 inhibitor and therefore does not require any ETI dose adjustment when co-prescribed.
ANSWER: A
Rationale:
Ivacaftor is metabolized primarily by cytochrome P450 isoform CYP3A4 (CYP3A4), and itraconazole is a strong CYP3A4 inhibitor. When a strong CYP3A4 inhibitor such as itraconazole, voriconazole, posaconazole, or ketoconazole is co-administered with any ivacaftor-containing regimen including ETI, ivacaftor plasma concentrations rise substantially because its hepatic metabolism is blocked; the prescribing labeling requires reducing the dosing frequency of the ETI regimen to every other day for the duration of concurrent strong inhibitor therapy. This dose adjustment is specified in the ETI label and must be documented at each encounter where an azole antifungal is initiated or continued, since CF patients frequently require antifungal therapy and this interaction recurs throughout the patient's treatment course. The every-other-day schedule reduces ivacaftor (and corrector) exposure to a level that remains therapeutic while avoiding potentially excessive ivacaftor concentrations.
Option B: Option B is incorrect because a defined dose-adjustment protocol exists per labeling; complete ETI discontinuation is not required or appropriate when a strong inhibitor is co-prescribed.
Option C: Option C is incorrect because the relevant interaction is pharmacokinetic (CYP3A4 inhibition raising ivacaftor concentrations), not merely a shared hepatotoxicity risk requiring only monitoring; failing to adjust the ETI dose exposes the patient to supratherapeutic ivacaftor levels.
Option D: Option D is incorrect because itraconazole inhibits CYP3A4-mediated metabolism and would increase, not decrease, ETI bioavailability; adding a dose would compound drug accumulation, not correct a deficit.
Option E: Option E is incorrect because voriconazole is also a strong CYP3A4 inhibitor and carries the same dose-adjustment requirement as itraconazole; it is not a moderate inhibitor and does not represent a safe alternative that avoids the interaction.
8. A 31-year-old man with cystic fibrosis (CF) is found on repeat genotyping to carry two class I CFTR mutations: G542X on one allele and W1282X on the other. He has seen reports about the benefits of elexacaftor-tezacaftor-ivacaftor (ETI) and asks whether he is eligible. Which of the following best explains why class I mutation homozygotes currently have no approved CFTR modulator option?
A) Class I mutations produce CFTR protein that reaches the apical membrane in normal amounts but with severely reduced conductance through the channel pore; potentiators and correctors cannot improve conductance defects caused by structural pore mutations.
B) Class I mutations are associated with the mildest clinical CF phenotype and generally do not require modulator therapy because residual CFTR function is sufficient for adequate chloride transport without pharmacological augmentation.
C) Class I mutations produce CFTR that is correctly folded and traffics normally to the apical membrane but cannot be opened by available potentiators because the adenosine triphosphate (ATP)-binding domains are structurally absent in truncated proteins.
D) Class I nonsense and frameshift mutations produce premature stop codons that trigger nonsense-mediated mRNA decay (NMD), resulting in absent or severely truncated CFTR protein with no functional channel at the apical membrane; correctors require misfolded protein to stabilize and potentiators require surface-expressed channel to act upon, so both drug classes lack a pharmacological target in this genotype.
E) Class I mutations occur only in non-Western populations in whom ETI has not been clinically tested, so current regulatory approvals do not extend to these patients on the basis of insufficient trial representation rather than pharmacological incompatibility.
ANSWER: D
Rationale:
Class I CFTR mutations, which include nonsense mutations such as G542X and W1282X as well as frameshift mutations, introduce premature stop codons into the CFTR mRNA. These premature stop codons trigger nonsense-mediated mRNA decay (NMD), a cellular surveillance mechanism that degrades mRNAs containing premature stop codons to prevent production of truncated, potentially dominant-negative proteins; the result is absent or severely truncated CFTR protein with no functional channel present at the apical epithelial membrane. CFTR correctors such as lumacaftor, tezacaftor, and elexacaftor act by stabilizing misfolded CFTR protein in the endoplasmic reticulum (ER) — they require the presence of a misfolded but translatable protein to rescue; there is no such protein to act upon when NMD has eliminated the mRNA. CFTR potentiators such as ivacaftor act by increasing the open probability of CFTR channels already at the apical membrane — without surface-expressed CFTR, potentiators have no pharmacological target. This is why patients with two class I mutations and no F508del allele have no currently approved modulator option.
Option A: Option A is incorrect because reduced conductance through the pore describes class IV mutations, not class I; class I mutations result in absent protein, not structurally present but conductance-impaired channels.
Option B: Option B is incorrect because class I mutations are among the most severe CF genotypes, associated with complete loss of CFTR function and the most significant clinical disease burden; they are not mild phenotypes.
Option C: Option C is incorrect because class I CFTR protein does not reach the apical membrane normally; the protein is absent or severely truncated due to NMD, not normally trafficked but unable to be opened.
Option E: Option E is incorrect because the reason for lack of approval is pharmacological — no target exists for currently available modulators — not a matter of trial enrollment geography; both G542X and W1282X occur across diverse populations.
9. A first-year resident asks about the distinction between CFTR correctors and potentiators when reviewing a patient's elexacaftor-tezacaftor-ivacaftor (ETI) prescription. Which of the following best describes the cellular mechanism by which CFTR correctors such as lumacaftor, tezacaftor, and elexacaftor produce their therapeutic effect?
A) They bind to CFTR at the apical membrane and increase the probability that the channel gate remains open during ATP hydrolysis, amplifying chloride conductance through channels that have already completed trafficking.
B) They bind to misfolded F508del CFTR protein in the endoplasmic reticulum (ER), stabilize its conformation, reduce recognition and degradation by the ER-associated degradation (ERAD) quality control machinery, and allow a greater fraction of CFTR to complete folding, traffic through the Golgi, and reach the apical cell membrane.
C) They suppress the expression of the Hsp70/Hsp90 chaperone complex that normally identifies misfolded proteins, broadly reducing ER quality control surveillance and allowing a wider range of misfolded proteins — including F508del CFTR — to escape degradation and reach the membrane.
D) They covalently modify the premature stop codon in class I CFTR mRNA to restore an open reading frame, producing partial-length functional CFTR that can then be potentiated by ivacaftor at the cell surface.
E) They activate the cAMP-protein kinase A (PKA) signaling axis to phosphorylate the regulatory R domain of CFTR, converting constitutively closed channels into channels capable of responding to ATP and opening in response to normal physiological stimuli.
ANSWER: B
Rationale:
CFTR correctors act at the endoplasmic reticulum (ER) level to rescue the processing defect that characterizes class II mutations such as F508del. The F508del mutation produces a CFTR protein that misfolds in the ER, primarily due to instability of the nucleotide-binding domain-1 (NBD1), and is recognized by the ER quality control machinery — including the Hsp70 and Hsp90 chaperone-cochaperone system — as abnormal; the misfolded protein is then ubiquitinated and targeted for proteasomal degradation through endoplasmic reticulum-associated degradation (ERAD) before it can complete trafficking to the apical membrane. Correctors bind directly to F508del CFTR (at binding sites that differ between first- and second-generation correctors) and stabilize its conformation, reducing ERAD recognition and allowing a substantially greater fraction of the synthesized CFTR protein to complete the folding process, transit through the Golgi, and traffic to the apical epithelial cell membrane where it can function as a chloride channel. Because F508del CFTR also retains a gating defect even after successful trafficking, correctors must be combined with a potentiator (ivacaftor) for full therapeutic effect.
Option A: Option A is incorrect because increasing the open probability of CFTR at the apical membrane is the mechanism of CFTR potentiators, not correctors; correctors act upstream at the ER trafficking level.
Option C: Option C is incorrect because correctors do not broadly suppress Hsp70/Hsp90 expression; they interact directly with CFTR protein to stabilize its conformation, which is a targeted rescue rather than a global suppression of ER quality control.
Option D: Option D is incorrect because correctors do not modify CFTR mRNA or address premature stop codons; read-through of class I nonsense mutations is an investigational strategy distinct from corrector pharmacology.
Option E: Option E is incorrect because activation of the cAMP-PKA pathway to phosphorylate the regulatory R domain is a normal physiological signal for CFTR gating, not the corrector mechanism; correctors act on protein folding, not on downstream signaling.
10. A CF center is reviewing the genotypes of four patients to determine eligibility for elexacaftor-tezacaftor-ivacaftor (ETI). Patient 1 is homozygous F508del; Patient 2 carries F508del on one allele and G542X (a class I nonsense mutation) on the other; Patient 3 carries F508del on one allele and G551D (a class III gating mutation) on the other; Patient 4 carries G542X on one allele and W1282X (another class I nonsense mutation) on the other. Which patients are eligible for ETI per current US FDA approval?
A) Patient 1 only, because the pivotal ETI trials enrolled exclusively F508del homozygotes and regulatory approval is limited to that genotype; heterozygous patients with any second allele other than F508del must use ivacaftor monotherapy or tezacaftor-ivacaftor.
B) Patients 1 and 3 only, because ETI requires two copies of an F508del-related mutation for the dual-corrector mechanism to engage both alleles simultaneously; heterozygotes with one non-F508del allele derive insufficient benefit to meet the approval threshold.
C) Patients 1, 2, and 3, but not Patient 4, because ETI requires at least one F508del allele regardless of what the second allele is, and is approved for patients aged 6 years and older; Patient 4 has no F508del allele and therefore has no target for the corrector components of the regimen.
D) All four patients, because ETI received broad approval for all CF patients regardless of genotype based on its exceptional efficacy in F508del homozygotes, with genotyping now considered optional prior to prescribing.
E) Patients 1, 2, and 3 are all eligible because ETI is approved for patients aged 2 years and older who carry at least one F508del allele — whether homozygous, compound heterozygous with a minimal function allele (as in Patient 2), or compound heterozygous with a residual function allele (as in Patient 3) — while Patient 4, who carries two class I mutations with no F508del allele, has no approved modulator option.
ANSWER: E
Rationale:
Elexacaftor-tezacaftor-ivacaftor (ETI) is approved in the United States for patients aged 2 years and older who carry at least one F508del CFTR allele, encompassing three genotypic subgroups: F508del homozygotes (two copies of F508del, as in Patient 1), compound heterozygotes with one F508del allele and one minimal function allele (class I nonsense or frameshift mutations that produce no functional CFTR, as in Patient 2 with F508del/G542X), and compound heterozygotes with one F508del allele and one residual function allele (class III, IV, or V mutations that produce some functional CFTR, as in Patient 3 with F508del/G551D). The common requirement across all three groups is at least one F508del allele, because the corrector components elexacaftor and tezacaftor are specifically designed to rescue F508del CFTR from ER-associated degradation; ivacaftor then potentiates the F508del CFTR that reaches the membrane as well as the G551D CFTR in Patient 3. Patient 4 (G542X/W1282X) carries two class I mutations with no F508del allele; without any F508del protein present, the correctors have no target, and current modulator approvals do not extend to this genotype. Approximately 85 to 90 percent of CF patients carry at least one F508del allele and are therefore ETI-eligible.
Option A: Option A is incorrect because ETI is not restricted to F508del homozygotes; the VX-445-102 trial's most striking results were in F508del heterozygotes with minimal function mutations, and approval explicitly includes heterozygotes.
Option B: Option B is incorrect because ETI eligibility requires at least one F508del allele, not two; the correctors act on whichever allele carries F508del, and compound heterozygotes benefit substantially.
Option C: Option C is incorrect because it states ETI is approved for patients aged 6 years and older; the current US FDA approval extends to patients aged 2 years and older, a threshold established by pediatric pharmacokinetic and efficacy data in children aged 2 to 5 years and reflecting the rationale that early CFTR rescue before irreversible bronchiectasis accrues produces greater long-term benefit. The correct minimum age is 2 years, not 6 years.
Option D: Option D is incorrect because ETI approval is genotype-specific and requires at least one F508del allele; genotyping is mandatory before prescribing.
11. The VX-445-102 phase 3 trial was the pivotal study that led to the approval of elexacaftor-tezacaftor-ivacaftor (ETI). Which of the following best describes the primary efficacy results of the VX-445-102 trial and the patient population that generated its most notable finding?
A) The trial enrolled 161 F508del homozygous patients and demonstrated a 10.0 percentage-point improvement in forced expiratory volume in one second as percent predicted (FEV1% predicted) compared with tezacaftor-ivacaftor alone, confirming incremental benefit of the triple combination over the dual regimen in patients who had already achieved some corrector rescue.
B) The trial enrolled exclusively patients with G551D gating mutations and demonstrated a 13.8 percentage-point FEV1% predicted improvement compared with ivacaftor monotherapy, establishing that elexacaftor adds corrector activity that synergizes with ivacaftor in gating mutation patients.
C) The trial enrolled 403 patients aged 12 and older with one F508del allele and one minimal function allele (a class I mutation producing no functional CFTR), and demonstrated a mean improvement in FEV1% predicted of 13.8 percentage points compared with placebo along with a 41.8 mmol/L sweat chloride reduction, a population that had no prior approved modulator option before ETI.
D) The trial enrolled patients with two class I mutations and no F508del allele and demonstrated a 13.8 percentage-point FEV1% predicted improvement on ETI compared with best supportive care, establishing ETI as the first modulator effective across all CFTR genotypes including class I homozygotes.
E) The trial was a head-to-head comparison of ETI versus lumacaftor-ivacaftor in F508del homozygotes and demonstrated a 13.8 percentage-point superiority of ETI over lumacaftor-ivacaftor, confirming the triple combination as the preferred first-line corrector regimen for all F508del patients.
ANSWER: C
Rationale:
The VX-445-102 trial enrolled 403 patients aged 12 and older who carried one F508del allele and one minimal function allele — that is, a class I mutation such as a nonsense or frameshift mutation that produces no functional CFTR protein. This population had no prior approved modulator option because earlier corrector-potentiator regimens required two copies of an amenable mutation, and ivacaftor monotherapy was not effective because F508del/minimal-function patients lack the surface-expressed CFTR that potentiators require. The trial demonstrated a mean improvement in forced expiratory volume in one second as percent predicted (FEV1% predicted) of 13.8 percentage points compared with placebo, a reduction in sweat chloride of 41.8 mmol/L, and significant improvement in the CF questionnaire-revised (CFQ-R) respiratory domain score. The magnitude of these results — the largest FEV1 gain seen in any CFTR modulator trial at the time — reflected the fact that ETI was the first regimen offering meaningful CFTR rescue to patients heterozygous for F508del with a minimal function second allele. A parallel arm of the same trial enrolled F508del homozygotes and showed a 10.0 percentage-point FEV1 improvement compared with tezacaftor-ivacaftor, confirming additional benefit of the triple combination even over the dual regimen.
Option A: Option A is incorrect because the 10.0 percentage-point result in F508del homozygotes compared with tezacaftor-ivacaftor was from a parallel arm of the trial, not the primary or most notable finding; the 13.8 percentage-point result in F508del/minimal-function heterozygotes was the trial's landmark outcome.
Option B: Option B is incorrect because the VX-445-102 trial did not enroll G551D patients; the STRIVE trial enrolled G551D patients and reported the 10.6 percentage-point ivacaftor result.
Option D: Option D is incorrect because ETI is not approved for patients with two class I mutations and no F508del allele; the VX-445-102 trial did not enroll this population, and this genotype remains without an approved modulator.
Option E: Option E is incorrect because VX-445-102 was not a head-to-head comparison against lumacaftor-ivacaftor; the F508del homozygous arm compared ETI against tezacaftor-ivacaftor as the active comparator.
12. A 34-year-old man with cystic fibrosis (CF) on elexacaftor-tezacaftor-ivacaftor (ETI) is found to have nontuberculous mycobacteria (NTM) lung disease. His infectious disease consultant proposes a multidrug regimen that includes rifampin. Which of the following best describes the consequence of adding rifampin to his ETI regimen and the appropriate management?
A) Rifampin is a strong inducer of cytochrome P450 isoform CYP3A4 (CYP3A4) and would markedly reduce plasma concentrations of ivacaftor and the corrector components of ETI to sub-therapeutic levels; rifampin should generally be avoided with any ivacaftor-containing regimen, and antibiotic selection for NTM must account for this restriction.
B) Rifampin is a weak CYP3A4 inhibitor that would modestly increase ETI plasma concentrations; the standard every-other-day dose adjustment used for azole antifungals can be applied, and ETI can be safely continued at that modified dose without further pharmacokinetic concern.
C) Rifampin has no clinically significant interaction with ETI because the corrector components elexacaftor and tezacaftor are not CYP3A4 substrates and would buffer any reduction in ivacaftor concentrations by maintaining adequate CFTR rescue through the corrector mechanism alone.
D) Rifampin activates the pregnane X receptor (PXR) to upregulate CYP3A4, but because ETI contains two corrector components that are not primarily CYP3A4-metabolized, only the ivacaftor component is affected; splitting ETI so that only the evening ivacaftor dose is held resolves the interaction while maintaining corrector activity.
E) Rifampin is contraindicated only with lumacaftor-ivacaftor because of the compounding CYP3A4 induction between rifampin and lumacaftor; tezacaftor-ivacaftor and ETI do not share this restriction because tezacaftor and elexacaftor are CYP3A4 inducers themselves and therefore insensitive to rifampin's induction effects.
ANSWER: A
Rationale:
Rifampin is a potent inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), the primary enzyme responsible for the metabolism of ivacaftor. When rifampin is co-administered with any ivacaftor-containing regimen — including ivacaftor monotherapy, tezacaftor-ivacaftor, or elexacaftor-tezacaftor-ivacaftor (ETI) — it induces CYP3A4 and markedly increases ivacaftor metabolism, reducing ivacaftor plasma concentrations to levels that may be below therapeutic concentrations. The prescribing labeling for ivacaftor-containing regimens classifies strong CYP3A4 inducers including rifampin, carbamazepine, phenytoin, and St. John's wort as agents that should be avoided in combination with any CFTR modulator containing ivacaftor. This interaction creates a clinically important challenge in CF because NTM lung disease is a recognized pulmonary complication of CF and rifampin is a component of standard multidrug NTM regimens; antibiotic selection for NTM infection in CF patients on modulator therapy must account for this restriction and may require rifampin-free alternative regimens or temporary modulator interruption under specialist guidance.
Option B: Option B is incorrect because rifampin is a strong CYP3A4 inducer, not a weak inhibitor; it reduces rather than increases ETI concentrations, and the every-other-day adjustment used for CYP3A4 inhibitors is not applicable to an inducer interaction.
Option C: Option C is incorrect because ivacaftor is an essential potentiator component of all F508del-targeted regimens; correctors alone cannot provide full therapeutic benefit because F508del CFTR reaching the membrane still requires potentiation, and sub-therapeutic ivacaftor concentrations compromise efficacy.
Option D: Option D is incorrect because splitting the ETI regimen to hold only the evening ivacaftor dose is not an established management strategy and would not adequately address the continuous CYP3A4 induction by rifampin, which accelerates ivacaftor metabolism throughout the day.
Option E: Option E is incorrect because the rifampin interaction applies to all ivacaftor-containing regimens, not only lumacaftor-ivacaftor; the concern is rifampin's CYP3A4 induction reducing ivacaftor concentrations, which applies equally to ETI.
13. A 17-year-old newly initiated on elexacaftor-tezacaftor-ivacaftor (ETI) asks her physician how often she will need blood tests to check her liver. Which of the following correctly states the liver function test (LFT) monitoring schedule specified in ETI prescribing labeling for a patient who has remained clinically well and without hepatic symptoms?
A) Liver function tests (LFTs) are required only at baseline before ETI initiation and are then repeated only if the patient develops symptoms of hepatotoxicity such as jaundice or right upper quadrant pain; routine asymptomatic monitoring is not specified in the labeling for clinically stable patients.
B) LFTs should be obtained monthly for the first year of ETI therapy, then every 3 months thereafter, because the risk of hepatotoxicity is highest in the first 12 months and requires intensive early surveillance before transitioning to less frequent maintenance monitoring.
C) LFTs should be checked at baseline, then at 1 month, 3 months, 6 months, and 12 months after ETI initiation, and then every 6 months indefinitely, with ETI interruption required if alanine aminotransferase (ALT) exceeds three times the upper limit of normal (ULN) at any point.
D) LFTs should be measured before starting ETI, at 3 months after initiation, and then annually in clinically stable patients; if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds five times the upper limit of normal (ULN) without symptoms, or three times the ULN with symptoms of liver toxicity, ETI should be interrupted.
E) LFTs are not routinely required for ETI monitoring because the hepatotoxicity risk with the triple combination is substantially lower than with prior corrector regimens such as lumacaftor-ivacaftor; monitoring is reserved for patients with pre-existing liver disease or CF-related liver disease at the discretion of the treating physician.
ANSWER: D
Rationale:
The prescribing labeling for elexacaftor-tezacaftor-ivacaftor (ETI) specifies that liver function tests (LFTs) — specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST) — should be measured before initiating ETI therapy, at 3 months after initiation, and then annually in clinically stable patients thereafter. This monitoring schedule reflects the known risk of transaminase elevations with ETI, which occurs in a subset of patients and requires active surveillance even in the absence of symptoms. The threshold for action specified in labeling is: if ALT or AST exceeds five times the upper limit of normal (ULN) without symptoms of liver toxicity, or three times the ULN with symptoms (jaundice, right upper quadrant pain, nausea), ETI should be interrupted and liver function reassessed; more frequent monitoring is required if elevations occur or if the patient has pre-existing liver disease, including CF-related liver disease, which itself affects approximately 30 percent of CF patients to some degree. Patients and clinicians must maintain this monitoring schedule as a standing component of ETI management.
Option A: Option A is incorrect because the labeling specifies proactive routine monitoring at defined intervals, not symptom-triggered monitoring only; asymptomatic LFT elevation above the ULN thresholds warrants action independent of symptoms.
Option B: Option B is incorrect because monthly LFT monitoring is not specified in the ETI labeling for routine stable patients; the labeled schedule is baseline, 3 months, then annually.
Option C: Option C is incorrect because the labeled monitoring intervals and interruption thresholds do not match the schedule described; the correct threshold for interruption without symptoms is five times the ULN, not three times, and the monitoring frequency described is more intensive than labeled for stable patients.
Option E: Option E is incorrect because routine LFT monitoring is specified in the ETI label and is not conditional on pre-existing liver disease; all ETI patients require the defined monitoring schedule regardless of baseline hepatic status.
14. An attending physician asks a student to explain why dornase alfa (recombinant human DNase I) reduces mucus viscosity in cystic fibrosis (CF) airway disease. Which of the following correctly describes the mechanism by which dornase alfa improves airway secretion rheology?
A) Dornase alfa inhibits mucin cross-linking by blocking the disulfide bond formation between MUC5AC and MUC5B mucin glycoproteins, directly reducing mucus gel viscosity by disrupting the polymer network responsible for abnormal mucus elasticity in CF airways.
B) Dornase alfa is a recombinant human deoxyribonuclease (DNase I) that degrades high-molecular-weight extracellular deoxyribonucleic acid (DNA) released by neutrophils during chronic airway infection and inflammation; this DNA is a major contributor to CF mucus viscosity, and its enzymatic cleavage reduces mucus stiffness and improves sputum clearance and rheology.
C) Dornase alfa osmotically draws water onto the airway surface by generating hyperosmolar conditions in the airway lumen when injected extracellular DNA fragments attract water molecules, hydrating the periciliary liquid layer and restoring normal mucociliary clearance.
D) Dornase alfa activates CFTR-independent chloride channels on the airway epithelium, bypassing the CFTR defect and restoring electrolyte secretion into the airway lumen, which secondarily dilutes and hydrates the accumulated mucus layer.
E) Dornase alfa competitively inhibits neutrophil elastase in the CF airway, reducing elastase-mediated cleavage of mucosal defense proteins and decreasing the inflammatory cascade that drives mucin hypersecretion and airway obstruction.
ANSWER: B
Rationale:
Dornase alfa is a recombinant human deoxyribonuclease I (DNase I) that catalyzes the hydrolytic cleavage of the phosphodiester backbone of extracellular deoxyribonucleic acid (DNA) into smaller fragments. In chronically infected CF airways, the massive influx of neutrophils recruited to combat bacterial colonization results in the release of large quantities of high-molecular-weight DNA when these cells undergo necrosis; this extracellular neutrophil-derived DNA becomes entangled within the mucus gel and dramatically increases its viscosity and elasticity, making sputum difficult for cilia to clear. Dornase alfa cleaves this DNA into smaller fragments, reducing the viscosity and elasticity of the sputum gel and improving its rheological properties so that airway clearance — both mucociliary and cough-dependent — becomes more effective. Dornase alfa was established as a CF therapy in the pre-modulator era and retains clinical relevance for patients with significant airway secretion burden, including those on ETI with established bronchiectasis who continue to require mucoactive therapy.
Option A: Option A is incorrect because dornase alfa does not act on mucin glycoproteins or their cross-linking; mucin-targeting agents such as N-acetylcysteine (which cleaves disulfide bonds) have a distinct mechanism, and disrupting mucin cross-links is not dornase alfa's pharmacological action.
Option C: Option C is incorrect because osmotic hydration of the airway surface liquid by generating hyperosmolar conditions is the mechanism of inhaled hypertonic saline, not dornase alfa; dornase alfa reduces viscosity through DNA degradation, not through osmotic water flux.
Option D: Option D is incorrect because dornase alfa is an extracellular DNA-cleaving enzyme and has no direct effect on ion channels; CFTR-independent chloride channel activation is not part of dornase alfa's mechanism.
Option E: Option E is incorrect because inhibiting neutrophil elastase is the mechanism of alpha-1 antitrypsin and related serine protease inhibitors, not dornase alfa; the two agents target different pathological processes in CF airway inflammation.
15. A 25-year-old woman with cystic fibrosis (CF) carries one F508del allele and one G551D allele (F508del/G551D compound heterozygote). Her physician is reviewing whether lumacaftor-ivacaftor (Orkambi) is an appropriate regimen for her. Which of the following correctly describes the approved indication for lumacaftor-ivacaftor and its applicability to this patient?
A) Lumacaftor-ivacaftor is approved for patients carrying at least one F508del allele regardless of the genotype at the second allele, making this patient with F508del/G551D fully eligible; the lumacaftor corrector addresses her F508del allele while ivacaftor potentiates both F508del and G551D CFTR simultaneously.
B) Lumacaftor-ivacaftor is approved for patients with one F508del allele plus any residual function mutation at the second allele, which would include G551D (a class III gating mutation); this patient would benefit because lumacaftor corrects her F508del processing defect while ivacaftor potentiates both alleles.
C) Lumacaftor-ivacaftor has no genotype restriction and is approved for all CF patients aged 2 and older regardless of mutation status, based on its acceptable safety profile and the general benefit of improved mucociliary clearance seen across all CF genotypes in post-marketing studies.
D) Lumacaftor-ivacaftor is not approved for any heterozygous patient because the corrector mechanism requires both CFTR alleles to carry F508del for cooperative stabilization; a patient with only one F508del allele lacks sufficient misfolded protein for lumacaftor to produce a meaningful clinical response.
E) Lumacaftor-ivacaftor is approved only for patients who are homozygous for F508del (two copies of F508del); this patient with F508del/G551D is not eligible for lumacaftor-ivacaftor, as the approval does not extend to compound heterozygotes, and she should instead be considered for regimens appropriate for her G551D allele plus F508del genotype.
ANSWER: E
Rationale:
Lumacaftor-ivacaftor (Orkambi) is approved specifically and only for patients aged 2 years and older who are homozygous for the F508del CFTR mutation — that is, patients with two copies of F508del. The pivotal TRAFFIC and TRANSPORT trials that supported its approval enrolled exclusively F508del homozygotes, and the approval did not extend to compound heterozygotes with one F508del allele and any other mutation at the second allele. This patient with F508del/G551D is therefore not eligible for lumacaftor-ivacaftor; for her specific compound heterozygous genotype (F508del with a class III gating mutation G551D at the second allele), she would be a candidate for tezacaftor-ivacaftor (which is approved for F508del plus residual function mutations) or for elexacaftor-tezacaftor-ivacaftor (which is approved for any patient with at least one F508del allele).
Option A: Option A is incorrect because lumacaftor-ivacaftor approval requires F508del homozygosity, not merely at least one F508del allele; the broader eligibility criterion described applies to ETI, not lumacaftor-ivacaftor.
Option B: Option B is incorrect because lumacaftor-ivacaftor is not approved for F508del heterozygotes with residual function mutations at the second allele; that broader indication applies to tezacaftor-ivacaftor (Symdeko), which is approved for F508del homozygotes and F508del/residual-function compound heterozygotes.
Option C: Option C is incorrect because lumacaftor-ivacaftor has specific genotype restrictions and is not approved across all CF genotypes; prescribing it outside its approved indication would be off-label and not supported by clinical evidence.
Option D: Option D is incorrect because the reason for limiting lumacaftor-ivacaftor to F508del homozygotes is not that the corrector mechanism requires two misfolded alleles cooperating; it reflects the clinical trial population and evidence base, and tezacaftor-ivacaftor does work in F508del heterozygotes despite the same single-allele corrector mechanism.
16. A CF care team is discussing why inhaled hypertonic saline (7% sodium chloride solution) improves mucociliary clearance in cystic fibrosis (CF) patients and whether it should be continued after initiating elexacaftor-tezacaftor-ivacaftor (ETI). Which of the following best describes the mechanism of action of inhaled hypertonic saline in CF airway disease?
A) Inhaled hypertonic saline activates calcium-dependent chloride channels (TMEM16A) on the airway epithelium, providing CFTR-independent chloride secretion that partially compensates for CFTR dysfunction and drives water secretion into the airway lumen by secondary ion gradients.
B) Inhaled hypertonic saline directly inhibits the epithelial sodium channel (ENaC), reducing sodium reabsorption and water absorption from the airway lumen, and thereby correcting the dehydration of the airway surface liquid layer that results from abnormally high ENaC activity in CF.
C) Inhaled hypertonic saline creates an osmotic gradient by depositing a high-concentration sodium chloride solution on the airway surface, drawing water from the submucosal tissue into the airway lumen and hydrating the mucus layer and periciliary liquid layer, reducing mucus viscosity and restoring mucociliary transport.
D) Inhaled hypertonic saline acidifies the airway surface liquid, and the lower pH directly disrupts bacterial biofilm integrity, reducing the chronic Pseudomonas aeruginosa burden in CF airways and thereby secondarily reducing the inflammatory-driven mucus hypersecretion that contributes to airway obstruction.
E) Inhaled hypertonic saline acts as a surfactant, reducing surface tension at the air-mucus interface and allowing mucus plugs to detach from airway walls with less expiratory force, improving cough-dependent secretion clearance independent of mucociliary transport.
ANSWER: C
Rationale:
In cystic fibrosis (CF), dysfunctional CFTR results in reduced chloride secretion and, secondarily, reduced water movement into the airway lumen, leading to dehydration of the airway surface liquid and periciliary liquid layer. This airway surface dehydration increases mucus viscosity and impairs the ability of cilia to beat efficiently and propel mucus toward the pharynx. Inhaled hypertonic saline (7% NaCl solution) works by creating an osmotic gradient: because the hypertonic solution deposited on the airway surface has a substantially higher sodium chloride concentration than the submucosal interstitium, water moves osmotically from the tissue into the airway lumen down this gradient, rehydrating the mucus layer and periciliary liquid layer and reducing mucus viscosity. This restoration of airway surface hydration improves mucociliary transport velocity and facilitates sputum clearance. The LCTR (Long-term Controlled Trial of Hypertonic Saline) trial demonstrated that long-term inhaled hypertonic saline reduces pulmonary exacerbations and modestly improves lung function in CF patients. Both hypertonic saline and dornase alfa retain clinical relevance in the ETI era for patients with established bronchiectasis and ongoing airway secretion burden, though the degree of benefit may require individual reassessment after modulator initiation.
Option A: Option A is incorrect because hypertonic saline does not activate TMEM16A calcium-dependent chloride channels; that strategy (pharmacological activation of alternative chloride channels) is a distinct investigational approach and not the mechanism of hypertonic saline.
Option B: Option B is incorrect because hypertonic saline does not directly inhibit the epithelial sodium channel (ENaC); ENaC inhibition is the mechanism of amiloride-based agents and, in the context of CF, is an investigational therapeutic target separate from osmotic hydration therapy.
Option D: Option D is incorrect because hypertonic saline does not act primarily through airway acidification or biofilm disruption; its mechanism is osmotic hydration, and while changes in pH and salt concentration may have secondary antimicrobial effects, this is not the primary therapeutic mechanism.
Option E: Option E is incorrect because hypertonic saline does not function as a surfactant; surfactant therapy targets alveolar surface tension in neonatal respiratory distress syndrome and is not the basis of hypertonic saline's mucokinetic action in CF.
17. A 28-year-old man with cystic fibrosis (CF) is found to have hyperglycemia on routine screening. His hemoglobin A1c (HbA1c) is 5.6%, which his primary care physician interprets as normal, and questions whether diabetes is truly present. His CF team suspects CF-related diabetes (CFRD). Which of the following best describes the preferred diagnostic approach and first-line treatment for CFRD, and why HbA1c alone is unreliable in this population?
A) Oral glucose tolerance testing (OGTT) is the preferred diagnostic method for CFRD because HbA1c may be falsely low in CF patients due to increased red blood cell turnover (shorter erythrocyte lifespan), which reduces the time available for hemoglobin glycosylation; when CFRD is confirmed, insulin therapy is preferred because it directly addresses the underlying insulin deficiency and may provide anabolic benefit in a nutritionally vulnerable population.
B) Fasting plasma glucose measurement on two separate occasions is the preferred diagnostic method for CFRD because fasting hyperglycemia is the earliest and most sensitive abnormality in CFRD; oral glucose tolerance testing (OGTT) is reserved for patients with equivocal fasting results, and metformin is preferred first-line therapy because CFRD involves insulin resistance similar to type 2 diabetes mellitus.
C) HbA1c at a threshold of 6.5% remains the diagnostic standard for CFRD and is preferred over oral glucose tolerance testing (OGTT) because CF patients frequently cannot tolerate the oral glucose load due to malabsorption; insulin therapy is preferred first-line treatment only if HbA1c exceeds 8.0% at diagnosis.
D) Continuous glucose monitoring (CGM) is the only validated diagnostic test for CFRD because intermittent glucose measurements miss the predominantly postprandial pattern of early CFRD; once confirmed, sulfonylurea therapy is preferred first-line because it stimulates residual beta-cell insulin secretion without the injection burden of insulin.
E) Urine glucose measurement (glycosuria screening) is the diagnostic standard for CFRD because the renal glucose threshold is lower in CF patients due to tubular dysfunction from pancreatic enzyme replacement; insulin analogs are avoided in CFRD because their prolonged action duration risks hypoglycemia in patients with erratic caloric intake from malabsorption.
ANSWER: A
Rationale:
CF-related diabetes (CFRD) has a pathophysiology distinct from both type 1 and type 2 diabetes mellitus: it results primarily from progressive destruction of pancreatic islet cells by the advancing pancreatic exocrine fibrosis that characterizes CF, producing relative insulin deficiency. CFRD typically presents with postprandial hyperglycemia before fasting hyperglycemia develops, which is why oral glucose tolerance testing (OGTT) — which measures the 2-hour plasma glucose response to a standardized 75-gram oral glucose load — is the preferred and most sensitive diagnostic test, capable of detecting early postprandial glucose dysregulation that fasting glucose and HbA1c may miss. HbA1c is specifically unreliable in CF patients because of increased red blood cell turnover: shorter erythrocyte lifespan in CF (related to chronic inflammation, hemolytic effects of repeated infections, and nutritional factors) reduces the time available for hemoglobin glycosylation, producing falsely low HbA1c values that underestimate the true degree of chronic glycemic exposure. Insulin therapy is the preferred first-line treatment for CFRD because it directly replaces the deficient pancreatic insulin secretion, avoids the risk of lactic acidosis associated with metformin in nutritionally compromised patients, and may have anabolic benefits important in a population prone to malnutrition and muscle wasting.
Option B: Option B is incorrect because fasting glucose is less sensitive for early CFRD than OGTT, since CFRD typically presents as postprandial rather than fasting hyperglycemia; metformin is not preferred in CFRD because the underlying defect is insulin deficiency, not insulin resistance, and metformin's mechanism is poorly suited to this pathophysiology.
Option C: Option C is incorrect because HbA1c at 6.5% is specifically unreliable in CF due to increased red blood cell turnover and is not recommended as the diagnostic standard for CFRD; OGTT is preferred precisely because HbA1c underestimates glycemic burden.
Option D: Option D is incorrect because while continuous glucose monitoring (CGM) can be a useful adjunct in CFRD management, it is not the current diagnostic standard; OGTT remains the recommended diagnostic test; and sulfonylureas, which stimulate insulin secretion, are generally not preferred given the progressive beta-cell destruction in CFRD.
Option E: Option E is incorrect because glycosuria screening is not the diagnostic standard for CFRD; renal glucose thresholds in CF patients are not reliably different from the general population in a way that validates urine glucose as a primary diagnostic tool, and the rationale described is not established in CFRD guidelines.
18. A pharmacology fellow is asked to explain why the triple combination elexacaftor-tezacaftor-ivacaftor (ETI) produces substantially greater F508del CFTR rescue than the dual combination tezacaftor-ivacaftor, despite both regimens containing tezacaftor and ivacaftor. Which of the following best explains the mechanistic basis of elexacaftor's additive benefit over tezacaftor alone?
A) Elexacaftor is a potentiator that binds to a second gating site on F508del CFTR distinct from ivacaftor's binding site, producing additive increases in open probability that together achieve near-normal chloride conductance not possible with ivacaftor alone.
B) Elexacaftor inhibits the ubiquitin E3 ligase that tags misfolded F508del CFTR for proteasomal degradation, reducing endoplasmic reticulum-associated degradation (ERAD) without directly binding to CFTR; when combined with tezacaftor, which directly stabilizes CFTR conformation, two complementary but molecularly distinct anti-degradation mechanisms act in parallel.
C) Elexacaftor is a transcriptional activator that upregulates CFTR gene expression in airway epithelium, increasing the total pool of F508del CFTR mRNA available for translation, so that even with the same fraction of misfolded protein escaping degradation, a greater absolute number of CFTR channels reach the apical membrane.
D) Elexacaftor is a next-generation CFTR corrector that binds to a site on F508del CFTR distinct from the tezacaftor binding site; simultaneous engagement of two structurally different regions of the misfolded F508del CFTR protein by elexacaftor and tezacaftor produces cooperative stabilization substantially greater than either corrector alone, explaining the superior efficacy of the triple combination.
E) Elexacaftor acts on mature CFTR at the apical membrane to prevent its accelerated internalization and lysosomal degradation, extending the surface lifetime of the CFTR that tezacaftor has already rescued from endoplasmic reticulum degradation and thereby amplifying the total chloride transport capacity per dose of corrector.
ANSWER: D
Rationale:
Elexacaftor is a next-generation CFTR corrector whose binding site on the F508del CFTR protein is distinct from the binding site of tezacaftor. When both correctors are administered simultaneously in the triple combination, they engage two structurally different regions of the misfolded F508del CFTR protein concurrently, producing cooperative conformational stabilization that is substantially greater than either corrector achieves alone. This dual-corrector synergy allows a much larger fraction of the F508del CFTR synthesized in the endoplasmic reticulum (ER) to complete folding, escape recognition by the ER-associated degradation (ERAD) quality control machinery, traffic through the Golgi, and reach the apical epithelial cell membrane. Ivacaftor then potentiates the gating of the F508del CFTR that reaches the membrane. The result — a 10 to 14 percentage-point forced expiratory volume in one second as percent predicted (FEV1% predicted) improvement over tezacaftor-ivacaftor alone in F508del patients — reflects the magnitude of this dual-corrector synergy. The mechanistic distinction between elexacaftor's and tezacaftor's binding sites is why the two correctors are additive rather than redundant.
Option A: Option A is incorrect because elexacaftor is a corrector, not a potentiator; it acts at the ER folding level, not at the apical membrane to increase gating probability.
Option B: Option B is incorrect because elexacaftor does directly bind to CFTR and acts through conformational stabilization rather than through ubiquitin E3 ligase inhibition; while ERAD is reduced by corrector action, the mechanism is direct CFTR binding, not an indirect anti-ubiquitination strategy.
Option C: Option C is incorrect because elexacaftor does not upregulate CFTR gene transcription or increase CFTR mRNA levels; it acts post-translationally on misfolded CFTR protein, not at the transcriptional or translational level.
Option E: Option E is incorrect because elexacaftor's mechanism is in the ER, not at the apical membrane to prevent internalization; stabilization of mature surface CFTR against internalization would describe a different class of agent not currently approved.
19. A medical student is reviewing CF mutation classes. She asks why patients with G551D (a class III gating mutation) respond well to ivacaftor monotherapy, whereas patients with F508del (a class II mutation) require both a corrector and a potentiator. Which of the following best explains the protein-level difference between class II and class III CFTR mutations that drives this therapeutic distinction?
A) Class III mutations produce CFTR protein that is completely absent from the cell because the G551D substitution introduces an in-frame stop codon, making the protein unavailable for pharmacological rescue; ivacaftor compensates by activating an alternative chloride channel that does not require CFTR.
B) Class III gating mutations such as G551D produce CFTR protein that folds normally and traffics in normal amounts to the apical epithelial membrane but cannot open appropriately in response to adenosine triphosphate (ATP) binding; because the CFTR protein is correctly processed and surface-expressed, ivacaftor monotherapy (which increases the open probability of surface-expressed CFTR) is sufficient without a corrector.
C) Class III mutations produce CFTR with reduced conductance through the channel pore due to altered transmembrane domain geometry; ivacaftor corrects pore geometry by binding within the transmembrane domains and restructuring the chloride permeation pathway, a mechanism that does not require prior corrector-mediated trafficking rescue.
D) Class III mutations cause CFTR mRNA instability and reduced translation efficiency, producing less CFTR protein overall; ivacaftor compensates by increasing the potency of each remaining CFTR channel to a degree sufficient to maintain near-normal chloride transport without the need for corrector-mediated protein quantity increases.
E) Both class II and class III mutations produce equivalent degrees of ER retention and protein misfolding; the difference is that G551D CFTR retains partial gating function that allows ivacaftor to amplify residual activity, whereas F508del CFTR is completely nonfunctional at the membrane and therefore requires corrector pretreatment to generate any target for potentiation.
ANSWER: B
Rationale:
Class III CFTR mutations, of which G551D (a glycine-to-aspartate substitution at position 551, located in nucleotide-binding domain-1 NBD1) is the most common, produce a CFTR protein that folds normally in the endoplasmic reticulum (ER) and traffics in normal or near-normal quantities through the Golgi apparatus to the apical epithelial cell membrane. The dysfunction in class III mutations is not a processing or trafficking defect but a gating defect: the G551D substitution impairs the protein's ability to bind or hydrolyze adenosine triphosphate (ATP) in a manner that normally opens the channel gate, so the CFTR channel sits at the membrane but remains closed the vast majority of the time. Because the problem is exclusively at the gating level and the CFTR protein is already surface-expressed in normal amounts, ivacaftor monotherapy — which binds to surface-expressed CFTR and increases the probability that the channel gate opens — is fully capable of addressing the entire defect without any need for corrector-mediated processing rescue. Class II mutations such as F508del, by contrast, produce CFTR that is trapped in the ER and degraded before reaching the membrane, so no surface-expressed channel exists for a potentiator to act upon; correctors must first rescue trafficking before potentiation can provide benefit.
Option A: Option A is incorrect because G551D is a missense mutation (substitution of aspartate for glycine), not a nonsense mutation; the protein is produced in normal amounts and traffics to the membrane; there is no alternative chloride channel activated by ivacaftor.
Option C: Option C is incorrect because reduced conductance through the channel pore is the hallmark of class IV mutations, not class III; G551D produces a gating defect, not a conductance or pore defect, and ivacaftor increases gate open probability, not pore geometry.
Option D: Option D is incorrect because class III mutations do not cause mRNA instability or reduced translation; the protein is produced and traffics normally, and the problem is gating, not protein quantity.
Option E: Option E is incorrect because class III mutations do not produce equivalent ER retention to class II mutations; the defining feature of class III is normal trafficking with gating failure, which is categorically different from class II processing retention.
20. A 20-year-old woman with cystic fibrosis (CF) homozygous for F508del is prescribed lumacaftor-ivacaftor (Orkambi). She takes a combined oral contraceptive pill for birth control. Her CF pharmacist flags a drug interaction. Which of the following best describes the interaction and the appropriate counseling for this patient?
A) Ivacaftor inhibits cytochrome P450 isoform CYP3A4 (CYP3A4) in a dose-dependent fashion, accumulating to inhibitory concentrations with the twice-daily dosing schedule and markedly increasing plasma estrogen and progestin concentrations to potentially supratherapeutic levels; she should switch to a lower-dose oral contraceptive formulation.
B) Lumacaftor competitively inhibits intestinal CYP3A4, increasing the bioavailability of orally administered estrogen and progestin, raising plasma hormone concentrations and potentially increasing the thromboembolic risk of combined oral contraceptives; she should be counseled about this increased risk.
C) Neither lumacaftor nor ivacaftor has a clinically significant interaction with oral contraceptives because oral contraceptives are primarily metabolized by CYP2C9 and UGT1A4 enzymes, which are unaffected by the CYP3A4 pharmacology of the lumacaftor-ivacaftor combination product.
D) Ivacaftor is a moderate inducer of cytochrome P450 isoform CYP3A4 (CYP3A4), reducing plasma concentrations of combined oral contraceptive steroids by approximately 20 to 30 percent; she should switch from a combined pill to a progestin-only pill, which is not metabolized by CYP3A4 and is unaffected by ivacaftor induction.
E) Lumacaftor is a strong inducer of CYP3A4, which substantially reduces plasma concentrations of the estrogen and progestin components of the oral contraceptive to potentially sub-therapeutic levels, significantly impairing contraceptive efficacy; she should be counseled to use a reliable non-hormonal contraception method while on lumacaftor-ivacaftor.
ANSWER: E
Rationale:
Lumacaftor is a strong inducer of cytochrome P450 isoform CYP3A4 (CYP3A4). The estrogen (ethinyl estradiol) and progestin components of combined oral contraceptives are metabolized substantially by CYP3A4; when lumacaftor strongly induces CYP3A4, it markedly accelerates the hepatic metabolism of these hormones, reducing their plasma concentrations to levels that may be insufficient for contraceptive efficacy. This interaction means that combined oral contraceptives, progestin-only pills, hormonal patches, and hormonal vaginal rings — all of which rely on maintaining therapeutic plasma hormone concentrations — may become ineffective contraceptive methods while the patient is on lumacaftor-ivacaftor. The prescribing labeling for lumacaftor-ivacaftor specifically notes that hormonal contraceptive efficacy may be reduced and recommends that patients use a reliable, non-hormonal method of contraception (such as condoms with spermicide, copper intrauterine device, or abstinence) while on this regimen. This interaction does not apply to tezacaftor-ivacaftor or ETI, because tezacaftor and elexacaftor do not induce CYP3A4, making them preferable for patients for whom hormonal contraception is important.
Option A: Option A is incorrect because ivacaftor is a CYP3A4 substrate, not a CYP3A4 inhibitor; the CYP3A4-interacting component is lumacaftor, and the interaction is induction (reducing hormone levels), not inhibition (raising them).
Option B: Option B is incorrect because lumacaftor is a CYP3A4 inducer, not an inhibitor; induction reduces, not increases, oral contraceptive plasma concentrations, and the direction of the effect is opposite to what is described.
Option C: Option C is incorrect because oral contraceptive steroids are metabolized significantly by CYP3A4, and lumacaftor's induction of CYP3A4 produces a clinically meaningful reduction in their plasma concentrations; the interaction is well-documented in the labeling.
Option D: Option D is incorrect because ivacaftor is not a CYP3A4 inducer; lumacaftor is the inducing component, and the degree of induction is strong, not moderate; progestin-only pills are also metabolized by CYP3A4 and would similarly be affected by lumacaftor induction.
21. A 29-year-old man with cystic fibrosis (CF) carries two class I CFTR mutations (G542X/W1282X) and has no F508del allele. His forced expiratory volume in one second as percent predicted (FEV1% predicted) has declined from 48% to 34% over the past 18 months. He asks whether any of the recently approved CFTR modulators could help him. Which of the following best describes the current therapeutic approach for this patient?
A) Elexacaftor-tezacaftor-ivacaftor (ETI) can be prescribed off-label for class I mutation patients because clinical series have demonstrated modest but measurable sweat chloride reductions with ETI in patients with at least one class I allele, and the FDA has recently expanded the compassionate use pathway to cover G542X/W1282X compound heterozygotes.
B) Ivacaftor monotherapy is appropriate for this patient because his W1282X allele produces a truncated CFTR protein with a residual gating defect that responds to potentiation; the G542X allele is inactive but does not inhibit the benefit of ivacaftor on the W1282X-produced channel.
C) No currently approved CFTR modulator is indicated for this patient; management relies on aggressive airway clearance, inhaled dornase alfa and hypertonic saline, prompt antibiotic treatment of pulmonary exacerbations, nutritional support with pancreatic enzyme replacement, and lung transplant evaluation given his declining lung function, with clinical trial enrollment actively discussed.
D) Tezacaftor-ivacaftor is appropriate for this patient because tezacaftor was specifically approved for patients with class I mutations at one allele regardless of the second allele's genotype, provided the patient has residual airway epithelial CFTR mRNA expression sufficient for corrector stabilization.
E) The patient should receive ataluren (a nonsense read-through agent) as primary CFTR-directed therapy because both his mutations are nonsense mutations amenable to read-through pharmacology; ataluren is approved by the FDA for this indication and can be combined with ivacaftor for synergistic CFTR functional restoration.
ANSWER: C
Rationale:
This patient carries two class I CFTR mutations (G542X and W1282X), both of which are nonsense mutations that introduce premature stop codons and trigger nonsense-mediated mRNA decay (NMD), resulting in absent or severely truncated CFTR protein with no functional channel present at the apical epithelial membrane. No currently approved CFTR modulator — whether corrector, potentiator, or triple combination — is indicated for patients with two class I mutations and no F508del allele, because all approved agents require either surface-expressed CFTR to potentiate or misfolded F508del CFTR to correct, neither of which is present in this genotype. Management for this modulator-ineligible patient relies on best supportive care: aggressive airway clearance therapy using positive expiratory pressure (PEP) devices or high-frequency chest wall oscillation (HFCWO) vests, inhaled dornase alfa to reduce mucus viscosity, inhaled hypertonic saline to hydrate the airway surface liquid, prompt and aggressive antibiotic treatment of pulmonary exacerbations, nutritional support including pancreatic enzyme replacement therapy for exocrine insufficiency, and fat-soluble vitamin supplementation. With FEV1% predicted declining to 34%, this patient is approaching the threshold at which lung transplant evaluation is indicated (generally FEV1% predicted below 30% or rapid decline), and referral for transplant evaluation should be actively pursued. Enrollment in clinical trials of investigational therapies — including read-through agents, RNA-targeted therapies, and next-generation modulators designed for class I mutations — should be actively discussed.
Option A: Option A is incorrect because ETI is not approved for patients with no F508del allele, no established off-label evidence base supports this specific use, and the FDA compassionate use pathway described does not exist as stated.
Option B: Option B is incorrect because ivacaftor requires surface-expressed CFTR to potentiate; truncated proteins from nonsense mutations that undergo NMD are absent from the membrane, and ivacaftor monotherapy does not benefit class I homozygotes.
Option D: Option D is incorrect because tezacaftor-ivacaftor is not approved for patients with class I mutations at either allele without F508del; the indication requires at least one F508del allele.
Option E: Option E is incorrect because ataluren is not FDA-approved for CF; it was studied in trials for CF with nonsense mutations but did not meet primary endpoints in phase 3 trials and has not received FDA approval for this indication.
22. A 38-year-old woman with CF who has been on elexacaftor-tezacaftor-ivacaftor (ETI) for 2 years asks whether her established bronchiectasis (documented on high-resolution CT chest) will reverse with continued modulator therapy. She also asks about the optimal age for initiating ETI in newly diagnosed CF patients. Which of the following best characterizes the current evidence regarding ETI's impact on pre-existing structural lung disease and the rationale for early initiation?
A) Current evidence indicates that structural lung damage present before ETI initiation — including bronchiectasis — does not regress significantly with ETI therapy; ETI can stabilize or slow further deterioration and reduce exacerbation rates, but irreversible airway remodeling that predates modulator therapy is not reversed, which underscores the benefit of initiating ETI as early as possible in life before cumulative airway damage occurs.
B) ETI produces progressive reversal of established bronchiectasis over 3 to 5 years of continuous therapy as measured by serial CT chest imaging, with the degree of reversal correlating with the sweat chloride reduction achieved; earlier initiation produces faster reversal because fewer irreversible cross-links have formed in the bronchiectatic airway walls.
C) Bronchiectasis in CF is an inflammatory rather than structural process and fully resolves when CFTR function is restored to near-normal levels by ETI; the apparent persistence of bronchiectatic changes on CT imaging after ETI initiation represents residual inflammatory thickening that resolves over 6 to 12 months as chronic infection clears.
D) ETI has no meaningful impact on the rate of pulmonary exacerbations or lung function decline once bronchiectasis is established; its benefit is confined to patients without yet-established structural disease, making late initiation (after the first exacerbation) the threshold at which modulator therapy becomes clinically futile.
E) The FDA approval of ETI for patients aged 2 and older is based on extrapolation from adult trial data rather than pediatric efficacy data; early initiation is currently not recommended pending completion of long-term pediatric safety studies, and established CF guidelines advise waiting until age 6 before initiating ETI.
ANSWER: A
Rationale:
Real-world registry data and extension trial follow-up from ETI studies consistently demonstrate that established bronchiectasis — the permanent dilation of airways resulting from repeated cycles of infection, inflammation, and airway wall destruction — does not regress significantly after ETI initiation, even with sustained CFTR functional restoration. ETI can stabilize lung function (FEV1% predicted), reduce pulmonary exacerbation frequency and severity, decrease hospitalization rates, and reduce sweat chloride to near-normal levels in many patients, but the irreversible structural remodeling of airway walls that characterizes established bronchiectasis represents permanent tissue changes that pharmacological CFTR restoration cannot undo. This finding has a critical implication for the timing of modulator therapy: the benefit of initiating ETI as early as possible in life — before cumulative airway damage accrues from years of CFTR dysfunction, repeated infections, and neutrophilic inflammation — is substantially greater than initiating therapy after bronchiectasis is already established. The FDA approval for patients aged 2 years and older reflects this rationale and is supported by pediatric trial data demonstrating safety and efficacy in young children.
Option B: Option B is incorrect because current evidence does not support progressive reversal of established bronchiectasis with ETI; CT imaging in ETI-treated patients shows stabilization of structural abnormalities, not regression, and sweat chloride reduction does not predict bronchiectasis reversal.
Option C: Option C is incorrect because bronchiectasis is a structural (not purely inflammatory) process involving permanent airway wall dilation, fibrosis, and destruction of the elastic airway wall architecture; it does not fully resolve when CFTR function is restored, and the CT findings represent permanent structural change, not transient inflammatory thickening.
Option D: Option D is incorrect because ETI does meaningfully reduce pulmonary exacerbations and slow lung function decline even in patients with established bronchiectasis; the therapy retains benefit in patients with structural disease, even though structural reversal does not occur.
Option E: Option E is incorrect because pediatric ETI efficacy and safety data do exist and informed the age 2 approval threshold; current guidelines do actively recommend ETI initiation in young children as early as the approval permits, not deferral until age 6.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.